ARTICLE | Distillery Therapeutics
Therapeutics: α-synuclein (SNCA); toll-like receptor 1 (TLR1); TLR2
June 11, 2015 7:00 AM UTC
Cell culture studies suggest inhibiting the TLR1/TLR2 heterodimer could help treat neuroinflammation in PD. In PD patients, levels of activated microglia, proinflammatory cytokines and oligomeric, mis...